|
|||||
|
|
VennVax, a DNA-prime, peptide-boost multi-T-cell epitope poxvirus vaccine, induces protective immunity against vaccinia infection by T cell response alone |
|
| Authors: | Moise Leonard Buller R Mark Schriewer Jill Lee Jinhee Frey Sharon E Weiner David B Martin William De Groot Anne S |
| Affiliation: | a EpiVax, Inc., Providence, RI, USA b University of Rhode Island, Providence, RI, USA c Saint Louis University School of Medicine, St. Louis, MO, USA d University of Massachusetts Medical Center, Worcester, MA, USA e Pediatric Infectious Disease, Brown University Warren Alpert Medical School, Providence, RI, USA f Department of Pathology, Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, USA |
| Abstract: | The potential for smallpox to be disseminated in a bioterror attack has prompted development of new, safer smallpox vaccination strategies. We designed and evaluated immunogenicity and efficacy of a T-cell epitope vaccine based on conserved and antigenic vaccinia/variola sequences, identified using bioinformatics and immunological methods. Vaccination in HLA transgenic mice using a DNA-prime/peptide-boost strategy elicited significant T cell responses to multiple epitopes. No antibody response pre-challenge was observed, neither against whole vaccinia antigens nor vaccine epitope peptides. Remarkably, 100% of vaccinated mice survived lethal vaccinia challenge, demonstrating that protective immunity to vaccinia does not require B cell priming. |
| Keywords: | Poxvirus vaccine T-lymphocyte epitopes Epitope-based vaccine Immunoinformatics |
| 本文献已被 ScienceDirect PubMed 等数据库收录！ | |